Main study: VICTORIA Main drivers of decision: Based on the data presented for the benefit assessment, the indication was split based on population age. A non-quantifiable added benefit of vericuguat for the endpoint hospitalisation for heart failure was evidenced only in indication 1 (patients <75 years). In the total population, a significant difference to the advantage of vericiguat was reported for the outcome atrial fibrillation, however, it was questioned whether the outcome belonged to the endpoint category side effects, or depicts the symptoms of the disease. A clear delimitation was not possible on the basis of the available information. Overall, there were no data to evidence the added benefit of treatment for patients ≥ 75 years (indication 2).